Novel gene delivery technology published and licensed exclusively to Cellinfinity Bio

WEST HAVEN, Conn. & SAN FRANCISCO–(BUSINESS WIRE)–Cellinfinity Bio, a privately held pioneer biotechnology company developing first/best-in-class cell therapy products against solid tumors and other diseases, today announced the publication of MAJESTIC (mRNA AAV–SB joint engineering of stable therapeutic immune cells), a technology that efficiently and with high cell health introduces…
Click here to view original post